文献速递消化内镜消化道肿瘤与早癌

内镜下黏膜切除术后腺瘤复发的治疗

Treatment of adenoma recurrence after endoscopic mucosal resection.
PubMed 文献 · Gut · 2023-07-06

该前瞻性队列研究在单中心139个月内纳入213例大无蒂结直肠息肉(≥20mm)内镜下黏膜切除(EMR)后腺瘤复发(RRA)患者,内镜下再治疗在符合方案分析中成功率为92.5%(149/161),意向性分析为73.8%(149/202),仅4.2%(9/213)需手术。

要点

  • RRA多较小(2.5-5.0mm占48.0%)且单灶(78.7%),简单内镜技术即可有效治疗。
  • 内镜治疗复发在符合方案分析中成功149/161(92.5%),意向性分析中成功149/202(73.8%),平均再治疗1.15次(SD 0.36)。
  • 仅9/213(4.2%,95%CI 2.2%至7.8%)RRA患者需手术,初治成功并随访者98.8%(159/161,95%CI 95.1%至99.8%)在中位13个月(IQR 25.0)随访内免于手术。

核心结论

  • EMR治疗大无蒂结直肠息肉后RRA可用简单内镜技术有效治疗,长期腺瘤缓解率>90%,仅16%需再治疗。
  • 因此,仅在选择病例中需要技术更复杂、并发症更多和资源更密集的内镜或手术技术。

研究设计与样本

  • 前瞻性队列研究,在一个三级内镜中心历时139个月,对单发大无蒂结直肠息肉(≥20mm)EMR后连续检出的RRA在结构化监测结肠镜检查中记录形态学和组织学数据。
  • 对存在RRA证据的病例进行内镜下再治疗,主要采用热圈套切除、冷撕脱钳联合圈套器尖端软凝固或两者联合。

主要发现

  • 213例(14.6%)患者出现RRA,其中168例(78.9%)在首次监测时发现,45例(21.1%)在此后发现。
  • RRA常见大小为2.5-5.0mm(48.0%),单灶占78.7%。
  • 202例(94.8%)有RRA宏观证据,其中194例(96.0%)成功接受内镜治疗,161例(83.4%)后续有随访结肠镜检查。
  • 内镜治疗复发在符合方案分析中成功149/161(92.5%),在意向性分析中成功149/202(73.8%),平均再治疗1.15次(SD 0.36)。
  • 无直接归因于内镜治疗的不良事件;内镜治疗后进一步RRA多数可经内镜治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Residual or recurrent adenoma (RRA) after endoscopic mucosal resection (EMR) of large non-pedunculated colorectal polyps (LNPCPs) of ≥20 mm is a major limitation. Data on outcomes of the endoscopic treatment of recurrence are scarce, and no evidence-based standard exists. We investigated the efficacy of endoscopic retreatment over time in a large prospective cohort. DESIGN: Over 139 months, detailed morphological and histological data on consecutive RRA detected after EMR for single LNPCPs at one tertiary endoscopy centre were prospectively recorded during structured surveillance colonoscopy. Endoscopic retreatment was performed on cases with evidence of RRA and was performed predominantly using hot snare resection, cold avulsion forceps with adjuvant snare tip soft coagulation or a combination of the two. RESULTS: 213 (14.6%) patients had RRA (168 (78.9%) at first surveillance and 45 (21.1%) thereafter). RRA was commonly 2.5-5.0 mm (48.0%) and unifocal (78.7%). Of 202 (94.8%) cases which had macroscopic evidence of RRA, 194 (96.0%) underwent successful endoscopic therapy and 161 (83.4%) had a subsequent follow-up colonoscopy. Of the latter, endoscopic therapy of recurrence was successful in 149 (92.5%) of 161 in the per-protocol analysis, and 149 (73.8%) of 202 in the intention-to-treat analysis, with a mean of 1.15 (SD 0.36) retreatment sessions. No adverse events were directly attributable to endoscopic therapy. Further RRA after endoscopic therapy was endoscopically treatable in most cases. Overall, only 9 (4.2%, 95% CI 2.2% to 7.8%) of 213 patients with RRA required surgery.Thus 159 (98.8%, 95% CI 95.1% to 99.8%) of 161 cases with initially successful endoscopic treatment of RRA and follow-up remained surgery-free for a median of 13 months (IQR 25.0) of follow-up. CONCLUSIONS: RRA after EMR of LNPCPs can be effectively treated using simple endoscopic techniques with long-term adenoma remission of >90%; only 16% required retreatment. Therefore, more technically complex, morbid and resource-intensive endoscopic or surgical techniques are required only in selected cases. TRIAL REGISTRATION NUMBERS: NCT01368289 and NCT02000141.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Tate DJ, Desomer L, Argenziano ME, et al. Treatment of adenoma recurrence after endoscopic mucosal resection. Gut. 2023. PMID: 37414440. doi:10.1136/gutjnl-2023-330300

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。